Mirvetuximab soravtansine demonstrated efficacy and tolerability in patients with platinum resistant ovarian cancer, according to phase 3 clinical data presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.
Previous treatment research has primarily focused on high-grade serous ovarian cancer, Ursula Matulonis, MD, a physician and chief of the division of gynecologic oncology at Dana-Farber Cancer Institute, told Healio. The findings of the current SORAYA study could lead to the approval of the antibody-drug conjugate — comprising a folate receptor